Acurx Pharmaceuticals LLC Ordinary Shares ACXP 深 滬
等待開盤 07-18 09:30:00 美东时间
0.449
+0.018
+4.27%
華盛通- 最 高0.46
- 今 開0.4529
- 成交量 42.90万股
- 最 低 0.44
- 昨 收 0.4306
- 總市值 1054.32万
- 52周最高 2.44
- 市盈率 靜 --
- 換手率 1.83%
- 52周最低 0.30
- 委 比 -33.89%
- 總股本 2348.16万
- 歷史最高 8.82
- 量 比 0.69
- 振 幅 4.64%
- 歷史最低 0.30
- 每 手 1
- 風險率 0.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Acurx Pharmaceuticals Holds Annual Meeting and Elections
Acurx Pharmaceuticals ( ($ACXP) ) has provided an update. On July 17, 2025, Acu...
今天 04:31
Acurx Pharmaceuticals files $50M mixed shelf offering
Acurx Pharmaceuticals (NASDAQ:ACXP) has filed a shelf registration to offer up to $50M in securities over time. The offering may include common stock, preferred stock, debt securities, warrants, right...
07-10 05:45
Acurx Pharmaceuticals Shares Are Up Today: What's Going On?
Shares of Acurx Pharmaceuticals inc. (NASDAQ: ACXP) are up on Tuesday following the publication of favorable clinical trial results and increased attention on the stock's micro-cap status.
06-18 02:57
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Acurx Pharmaceuticals (NASDAQ:ACXP) stock moved upwards by 235.5% to $...
06-17 20:08
Acurx Pharmaceuticals Announces Publication Of Results In Lancet Of Its Phase 2 Ibezapolstat Study
As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) recurrence
06-17 19:03
【美股盘前】伊以冲突推升石油股狂飙！SK海力士股价创20年新高！美国经济数据即将揭晓，美股能否再创新高？
伊以冲突持续，石油股继续受益大涨；SK海力士拟建造韩国最大AI数据中心，股价创下近20年新高；美国即将公布多项经济数据，美股将继续上涨？
06-17 11:36
Acurx Pharma Says Lead Antibiotic Candidate, Ibezapolstat, Is Ready To Advance To International Pivotal Phase 3 Clinical Trials For Treatment Of Patients With C. Difficile Infection
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC
06-09 19:31
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
HC Wainwright & Co. Assumes Acurx Pharmaceuticals at Buy, Announces Price Target of $8
HC Wainwright & Co. analyst Matthew Kelsey assumes Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy rating and announces Price Target of $8.
05-15 19:43
